Lack of commercial oral drug formulations for children in two hospital group purchasing agreements in France and Canada

International Journal of Pharmaceutical Compounding

Volumn 12, Issue 4, 2008, Pages 365-367

  Prot Labarthe, Sonia ^a   Bussières, Jean François ^a   Barret, Pierre ^a   Bourdon, Olivier ^b   Brion, Françoise ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIMYCOBACTERIAL AGENT; ANTIPARKINSON AGENT; ANTIVIRUS AGENT; CEPHALOSPORIN; DIGESTIVE TRACT AGENT; DIPHENHYDRAMINE; GENERIC DRUG; ISONIAZID; JOSAMYCIN; LINEZOLID; LORATADINE; PHENYTOIN; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RANITIDINE; VACCINE; VORICONAZOLE;

ARTICLE; CANADA; CLINICAL TRIAL; COMMERCIAL PHENOMENA; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG UTILIZATION; FRANCE; HOSPITAL; HUMAN; MULTICENTER STUDY; PEDIATRICS; THRUSH; URBAN AREA;

EID: 77949481785     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Avenel S, Bomkratz A, Dassieu G et al. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr 2000; 7(2): 143-147.
2. Combeau D, Fontan JE, Brion F. Drug formulary analysis in a pediatric hospital. J Pharm Clin 1999; 18(1): 5-10.
3. Turner S, Longworth A, Nunn AJ et al. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998; 316(7128): 343-345.
4. Eiland LS, Knight P. Evaluating the off-label use of medications in children. Am J Health Syst Pharm 2006; 63(11): 1062-1065.
5. Fontan JE, Mille F, Brion F et al. [Drug administration to paediatric inpatient]. Arch Pediatr 2004; 11(10): 1173-1184.
6. Koren G, Haslam RH. Pediatric medication errors: Predicting and preventing tenfold disasters. J Clin Pharmacol 1994; 34(11): 1043-1045.
7. Roberts R, Rodriguez W, Murphy D et al. Pediatric drug labeling: Improving the safety and efficacy of pediatric therapies. JAMA 2003; 290(7): 905-911.
8. Nahata MC. Lack of pediatric drug formulations. Pediatrics 1999; 104(3 Pt 2): 607-609.
9. [No author listed.] Réseau Mère-Enfant de la francophonie. [rme-francophonie.org Website.] Available at: www.rme-francophonie.org/fr/. Accessed October 23, 2006.
10. [No author listed.} Theriaque. Groupement d'Intérêt Economique - Système d'Information sur les Produits de Santé. Available at: www.theriaque.org. Accessed September 20, 2006.
11. [No author listed.] Health Canada. Drug Product Database. [Health Canada Website.] Available at: www.hc-sc.gc.ca/hpb/drugs-dpd/. Accessed September 20, 2006.
12. Brion F, Nunn AJ, Rieutord A. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr 2003; 92(4): 486-490.
13. Lévy L, Martin-Guehl C, Lechevallier-Michel N et al. Use of psychotropic drugs in 0 to 5 years old children in Aquitaine (France): Prevalence and associated factors. Pharmacoepidemiol Drug Saf 2006; 15(7): 504-509.
14. [No author listed.] Agence Français de Sécurité Sanitaire des Produits de Santé. Médicaments Pédiatriques. [Agence Français de Sécurité Sanitaire des Produits de Santé Website.] December 31, 2007. Available at: http://agmed.sante.gouv.fr/htm/1/grtrav/enfants/sommaire.htm. Accessed September 26, 2006.
15. [No author listed.] European Medicines' Agency. Medicines for Children-The European Paediatric Initiative. [EurActiv.com Website.] Available at: www.emea.eu.int/htms/human/peg/pegfaq.htm. Accessed October 23, 2006.